Findings of Scientific Misconduct, 61443 [05-21150]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 204 / Monday, October 24, 2005 / Notices
and approximately 3 p.m. on December
15.
Comments: Written comments should
be received by December 5, 2005, to
allow time for adequate review before
the workshop (see FOR FURTHER
INFORMATION CONTACT below). The
deadline for registration to present oral
comments at the meeting is December 8,
2005.
Registration: Individuals who plan to
attend are encouraged to register online
at the NTP Web site https://
ntp.niehs.nih.gov/ select ‘‘Meetings and
Workshops’’ as soon as possible because
seating is limited. Persons needing
special assistance, such as sign language
interpretation or other reasonable
accommodation in order to attend,
should contact 919–541–2475 voice,
919–541–4644 TTY (text telephone),
through the Federal TTY Relay System
at 800–877–8339, or by e-mail to
niehsoeeo@niehs.nih.gov. Requests
should be made at least 7 days in
advance of the event.
ADDRESSES: The workshop will be held
at the Hyatt Regency Crystal City, 2799
Jefferson Davis Highway, Arlington, VA.
FOR FURTHER INFORMATION CONTACT:
Public comments and any other
correspondence should be submitted to
Dr. Barbara Shane (NTP Liaison and
Scientific Review Office, NIEHS, P.O.
Box 12233, MD A3–01, Research
Triangle Park, NC 27709; telephone:
919–541–4253, fax: 919–541–0295; or email: shane@niehs.nih.gov).
SUPPLEMENTARY INFORMATION:
Dated: October 13, 2005.
Samuel H. Wilson,
Deputy Director, National Institute of
Environmental Health Sciences.
[FR Doc. 05–21130 Filed 10–21–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
Background
The High Throughput Screening
Assays Workshop will include plenary
sessions as well as four simultaneous
breakout group sessions for in-depth
discussion. Each breakout group will
address one of the following topics: (1)
The selection of targets and assays for
high throughput screening; (2) the
conduct of studies including chemical
selection, study design, and analytical
methods; (3) data storage, analysis, and
interpretation; and (4) the application of
data from high throughput screening
assays in regulatory decision-making.
Following the workshop, the NTP will
prepare a workshop report and present
its proposed strategy to the NTP Board
of Scientific Counselors for its
consideration and input.
Request for Comments
Public input at this meeting is invited
and time is set aside for the presentation
of public comments during the plenary
session on December 14. Each
organization is allowed one speaker
during the public comment period. At
VerDate Aug<31>2005
least 7 minutes will be allotted to each
speaker, and if time permits, may be
extended to 10 minutes. Registration for
oral comments will also be available onsite, although time allowed for
presentation by on-site registrants may
be less than that for pre-registered
speakers and will be determined by the
number of persons who register at the
meeting.
Written statements can supplement
and may expand the oral presentation.
If registering on-site and reading from
written text, please bring 40 copies of
the statement for distribution and to
supplement the record. Written
comments received in response to this
notice will be posted on the NTP Web
site (https://ntp.niehs.nih.gov select
‘‘Meetings and Workshops’’). Persons
submitting written comments should
include their name, affiliation, mailing
address, phone, fax, e-mail, and
sponsoring organization (if any) with
the document.
15:19 Oct 21, 2005
Jkt 208001
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Acting Assistant Secretary for
Health have taken final action in the
following case:
Xiaowu Li, MD, PhD, The University
of California at San Francisco: On
September 16, 2005, the U.S. Public
Health Service (PHS) entered into a
Voluntary Exclusion Agreement with
the University of California at San
Francisco (UCSF) and Xiaowu Li, MD,
PhD, former postdoctoral fellow at
UCSF. Based on the UCSF report and
additional analysis conducted by ORI in
its oversight review, PHS found that Dr.
Li engaged in scientific misconduct in
reporting research supported by grants
P01 DE13904, ‘‘Adhesion and
proliferation in oral cancer
progression,’’ R01 DE12856, ‘‘Oral
melanoma alpha v beta 3 expression and
metastasis,’’ and R01 DE011930,
‘‘Regulatory function of fyn in oral SCC
invasion,’’ all funded by the National
Institute of Dental and Craniofacial
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
61443
Research (NIDCR), National Institutes of
Health (NIH).
Specifically, PHS found that Dr. Li
falsified three images in Figure 5B of a
paper, ‘‘Laminin-5 promotes cell
motility by regulating the function of
the integrin a6b1 in pancreatic cancer,’’
published online in Carcinogenesis
Advance Access, reporting studies on
the role of integrin a6b1 and laminin on
the invasiveness of pancreatic cancer
cells and their ability to metastasize.
In all three images, mouse melanoma
cells were falsely represented as being
human pancreatic carcinoma cells; the
cancer cells were falsely represented as
having been plated on medium with
laminin-1, whereas they were in fact
plated on medium with vitronectin; and
for two of the three images, the cancer
cells were falsely represented as having
been stained with anti-integrin b1,
whereas they were actually stained with
anti-integrin b3.
The misconduct was significant
because pancreatic cancer has a poor
prognosis for patients, since it tends to
invade other tissues and to metastasize
early in its course. Knowledge of the
factors that facilitate cancer cell
invasion and metastasis, which was the
focus of the questioned figure and
paper, is crucial to attempts to develop
better treatments for pancreatic and
other cancers. Thus, the falsified figure
could have misled other investigators in
this important area of medical research.
Dr. Li has entered into a Voluntary
Exclusion Agreement (Agreement) in
which he has voluntarily agreed, for a
period of three (3) years, beginning on
September 16, 2005:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ as defined in the
debarment regulations at 45 CFR Part
76; and
(2) To exclude himself from serving in
any advisory capacity to PHS including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (301) 443–5330.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 05–21150 Filed 10–21–05; 8:45 am]
BILLING CODE 4150–31–P
E:\FR\FM\24OCN1.SGM
24OCN1
]]>Agencies
[Federal Register Volume 70, Number 204 (Monday, October 24, 2005)]
[Notices]
[Page 61443]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-21150]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Acting Assistant Secretary for Health have taken final
action in the following case:
Xiaowu Li, MD, PhD, The University of California at San Francisco:
On September 16, 2005, the U.S. Public Health Service (PHS) entered
into a Voluntary Exclusion Agreement with the University of California
at San Francisco (UCSF) and Xiaowu Li, MD, PhD, former postdoctoral
fellow at UCSF. Based on the UCSF report and additional analysis
conducted by ORI in its oversight review, PHS found that Dr. Li engaged
in scientific misconduct in reporting research supported by grants P01
DE13904, ``Adhesion and proliferation in oral cancer progression,'' R01
DE12856, ``Oral melanoma alpha v beta 3 expression and metastasis,''
and R01 DE011930, ``Regulatory function of fyn in oral SCC invasion,''
all funded by the National Institute of Dental and Craniofacial
Research (NIDCR), National Institutes of Health (NIH).
Specifically, PHS found that Dr. Li falsified three images in
Figure 5B of a paper, ``Laminin-5 promotes cell motility by regulating
the function of the integrin [alpha]6[beta]1 in pancreatic cancer,''
published online in Carcinogenesis Advance Access, reporting studies on
the role of integrin [alpha]6[beta]1 and laminin on the invasiveness of
pancreatic cancer cells and their ability to metastasize.
In all three images, mouse melanoma cells were falsely represented
as being human pancreatic carcinoma cells; the cancer cells were
falsely represented as having been plated on medium with laminin-1,
whereas they were in fact plated on medium with vitronectin; and for
two of the three images, the cancer cells were falsely represented as
having been stained with anti-integrin [beta]1, whereas they were
actually stained with anti-integrin [beta]3.
The misconduct was significant because pancreatic cancer has a poor
prognosis for patients, since it tends to invade other tissues and to
metastasize early in its course. Knowledge of the factors that
facilitate cancer cell invasion and metastasis, which was the focus of
the questioned figure and paper, is crucial to attempts to develop
better treatments for pancreatic and other cancers. Thus, the falsified
figure could have misled other investigators in this important area of
medical research.
Dr. Li has entered into a Voluntary Exclusion Agreement (Agreement)
in which he has voluntarily agreed, for a period of three (3) years,
beginning on September 16, 2005:
(1) To exclude himself from any contracting or subcontracting with
any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States Government
referred to as ``covered transactions'' as defined in the debarment
regulations at 45 CFR Part 76; and
(2) To exclude himself from serving in any advisory capacity to PHS
including but not limited to service on any PHS advisory committee,
board, and/or peer review committee, or as consultant.
For Further Information Contact: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 05-21150 Filed 10-21-05; 8:45 am]
BILLING CODE 4150-31-P
